A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

Mpox, previously called monkeypox, is a rare disease. Part of the same family as the virus that causes smallpox, it is caused by a type of virus typically found in West and Central Africa. It is ...

The Department for Health and Social Care has broadened access to the life-saving jab this month to prevent these hospitalisations and the 8,000 deaths associated with respiratory syncytial virus ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Following after are RSV vaccines from Johnson & Johnson as well as Moderna, in what is shaping gup to be a fiercely contested market. AZ, Sanofi antibody aces phase 3 trial ...

Mpox particles were found in routine wastewater tests in North Carolina. The particles were found in samples collected on ...